A detailed history of Captrust Financial Advisors transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 15,007 shares of CCCC stock, worth $60,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,007
Previous 14,822 1.25%
Holding current value
$60,928
Previous $68,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.43 - $7.38 $819 - $1,365
185 Added 1.25%
15,007 $85,000
Q4 2023

Feb 14, 2024

SELL
$1.18 - $6.03 $38 - $198
-33 Reduced 0.22%
14,822 $83,000
Q3 2023

Nov 14, 2023

SELL
$1.81 - $3.89 $3,393 - $7,293
-1,875 Reduced 11.21%
14,855 $27,000
Q2 2023

Aug 14, 2023

BUY
$2.75 - $3.77 $3,817 - $5,232
1,388 Added 9.05%
16,730 $46,000
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $47,560 - $138,384
15,342 New
15,342 $48,000
Q1 2022

May 16, 2022

SELL
$19.99 - $33.23 $98,750 - $164,156
-4,940 Reduced 25.0%
14,822 $360,000
Q4 2021

Feb 14, 2022

SELL
$29.39 - $46.86 $193,591 - $308,666
-6,587 Reduced 25.0%
19,762 $636,000
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $797,463 - $1.11 Million
26,241 Added 24297.22%
26,349 $997,000
Q1 2021

May 17, 2021

BUY
$31.96 - $46.5 $3,451 - $5,022
108 New
108 $4,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $199M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.